Belfast, Northern Ireland, United Kingdom, November 5, 2026
PulseAI, a medical technology company specializing in artificial intelligence-powered cardiac diagnostics, has announced that its AI-powered arrhythmia analysis model for wearable electrocardiogram (ECG) devices has received U.S. Food and Drug Administration (FDA) 510(k) clearance. The regulatory milestone represents an important advancement in digital cardiology, particularly in the use of artificial intelligence to improve the interpretation of heart rhythm recordings collected through smartwatches and other wearable devices. The technology is designed to analyze ECG recordings and support the identification of abnormal heart rhythms, including atrial fibrillation (AFib). According to the company, the system has the potential to improve diagnostic interpretation while reducing the number of inconclusive ECG results that require additional clinical review. The FDA clearance creates an opportunity for PulseAI to integrate its technology into compatible wearable ECG devices and digital health platforms, potentially expanding access to AI-assisted cardiac monitoring beyond conventional hospital environments.
AI Technology Aims to Improve Wearable ECG Accuracy
The increasing adoption of smartwatches and wearable health monitoring devices has made ECG recording more accessible to consumers. However, interpreting the large volume of patient-generated ECG recordings presents a significant challenge for healthcare professionals. Inconclusive readings can require manual assessment, repeat recordings and additional patient follow-up, increasing the workload for clinical teams. PulseAI’s artificial intelligence model is designed to address this challenge by applying advanced deep-learning algorithms to wearable ECG recordings. The company has developed its technology using millions of ECG recordings, with the objective of improving the recognition and interpretation of cardiac rhythm patterns. The platform is designed to work with compatible ECG devices and software applications, allowing recordings to be submitted for automated cloud-based analysis. Following processing, structured analysis results are returned to the connected application for clinical review. This approach could help healthcare providers manage increasing volumes of wearable-generated cardiac data while supporting more efficient diagnostic workflows. The technology is particularly relevant to atrial fibrillation, one of the most common sustained cardiac arrhythmias, which can increase the risk of ischemic stroke and other cardiovascular complications if left untreated.
Clinical Study Reports 92% Reduction in Inconclusive Results
The company’s announcement highlights findings from a prospective clinical study involving 296 participants, published in the peer-reviewed journal Heart Rhythm. In the study, PulseAI’s artificial intelligence algorithm was evaluated against the native ECG interpretation algorithm used by the Apple Watch. According to the reported findings, the PulseAI model improved atrial fibrillation detection sensitivity while demonstrating a 92% reduction in inconclusive ECG interpretations compared with the Apple Watch’s native algorithm. Reducing inconclusive results is an important objective in wearable cardiac monitoring because unresolved ECG recordings can create additional requirements for healthcare professionals to review data and request repeat measurements. By improving the interpretability of wearable ECG recordings, AI-powered analysis could potentially support more scalable cardiac monitoring services. The study provides clinical evidence supporting the company’s technology development, although the reported comparison should not be interpreted as proof that the system improves patient outcomes. Further clinical evaluation and real-world implementation will be important in establishing its performance across different wearable devices, patient populations and healthcare settings. The company has emphasized that its technology is intended to support clinical assessment rather than replace healthcare professionals.
Advertisement
FDA Clearance Opens New Digital Cardiology Opportunities
The FDA 510(k) clearance represents a significant regulatory milestone for PulseAI as it moves toward broader commercial integration of its cardiac diagnostic technology. The company plans to focus on bringing its AI-powered arrhythmia analysis capabilities into compatible wearable devices and digital health platforms already used by consumers and healthcare providers. The clearance could strengthen the role of AI-assisted ECG interpretation in remote cardiac monitoring, particularly as wearable devices increasingly become part of preventive healthcare and chronic disease management strategies. PulseAI Chief Executive Officer and Founder Dr. Alan Kennedy stated that the company’s ambition is to combine the growing accessibility of wearable ECG recording with improved interpretation accuracy to support scalable healthcare solutions. Founded in 2020, PulseAI is headquartered in Belfast, Northern Ireland, and focuses on developing deep-learning technologies for cardiac diagnostics. Its algorithms are designed for applications across smartwatches, wearable ECG patches, hospital monitoring systems and defibrillators. Innovation Ulster Limited, the investment arm of Ulster University, led the company’s recent investment round alongside the Mortara Group. The involvement of these organizations highlights the growing collaboration between academic research, medical technology companies and healthcare investors in advancing artificial intelligence-based diagnostic solutions. Overall, PulseAI’s FDA 510(k) clearance marks an important development in AI-powered wearable cardiac diagnostics. By combining deep-learning technology with accessible ECG monitoring, the company aims to address the growing demand for efficient cardiac rhythm analysis. The reported reduction in inconclusive ECG interpretations highlights the potential value of the technology for healthcare providers managing increasing volumes of wearable-generated data. Future integration into compatible devices and clinical workflows will determine the technology’s broader impact on digital cardiology and remote patient monitoring.
Source: PulseAI press release
